The P2Y (adenosine diphosphate) receptor blocker cangrelor administered shortly before reperfusion in rabbits undergoing 30-minute regional ischemia/3-hour reperfusion reduced infarction from 38% of ischemic zone in control hearts to only 19%. Protection was dose dependent and correlated with the degree...
Dual antiplatelet therapy with aspirin and a P2Y12 receptor blocker is a key strategy to reduce platelet reactivity and to prevent thrombotic events in patients treated with percutaneous coronary intervention. In an earlier consensus document, we proposed cutoff values for high on-treatment platelet ...
Much like to ticagrelor, the intravenous agent cangrelor directly and reversibly antagonizes ADP binding to the P2Y12 receptor. Cangrelor rapidly reaches steady state plasma levels and platelet aggregation inhibition within 30 min of onset of infusion without the need for a bolus dose, and the plasm...
Platelets express a wide range of receptors and proteins that play essential roles in thrombus formation. Among these, the P2Y12receptor, a member of the G protein-coupled receptor family, has attracted a significant amount of attention. Stimulation of the P2Y12receptor by ADP results in activatio...
Hence, there is clear need for additional/alternative IV P2Y12 blockers (with a better safety profile). In the present studies, we characterize an antibody targeting the platelet P2Y12 receptor (abbreviated P2Y12Ab) in terms of its function-blocking capacity, under in vitro and in vivo ...
Since the antiplatelet agent aspirin is associated with a reduce risk of death and dis- tant metastasis in cancer patients [25–27] including those with ovarian cancer [28], we investigated the effect of aspirin and the antiplatelet P2Y12 blocker, 2- methylthioadenosine 5′-monophosphate triethyl...
Many of the antiplatelet drugs are effective and useful in coronary disease but when it comes to the cerebral vascular diseases or stroke, heparin3,4 and antiplatelet drugs, GPIIb/IIIa inhibitors like abciximab5 or tirofiban6,7, P2Y12 blockers such as prasugrel8 or the thrombin-receptor antagoni...
(GPIs), is central to ACS treatment. Aspirin, which inhibits platelet activation by irreversibly binding to cyclooxygenase-1, is widely accepted as first-line treatment in ACS patients.2By irreversibly binding the platelet P2Y12receptor, thienopyridines inhibit adenosine dis...
Effect of GPIIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndrome without early coronary revascularisation:the GUSTO IV-ACS trial Lancet, 357 (2001), pp. 1915-1924 Google Scholar 84 Quinn MJ, Plow EF, Topol EJ Platelet glycoprotein IIb /IIIa inhibitors. Recogni...
platelet-immune cell interaction and platelet-endothelial cell interaction. Clinical modulations targeting platelet activation in the immune system include P2Y12receptor inhibitors, COX-1 inhibitors, 12-LOX inhibitors, IVg and SYK inhibitors, TLR7 inhibitors, NLRP3 and BTK inhibitors, IP receptor agonists...